Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials.

Patricia D'Souza M, Allen MA, Baumblatt JAG, Boggiano C, Crotty S, Grady C, Havenar-Daughton C, Heit A, Hu DJ, Kunwar N, McElrath MJ; Lymph Node Webinar Contributors.

Vaccine. 2018 Sep 11;36(38):5671-5677. doi: 10.1016/j.vaccine.2018.07.071. Epub 2018 Aug 7.

PMID:
30097219
2.

Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

McGuire AT, Glenn JA, Lippy A, Stamatatos L.

J Virol. 2014 Mar;88(5):2645-57. doi: 10.1128/JVI.03228-13. Epub 2013 Dec 18. Erratum in: J Virol. 2015 May;89(9):5194.

3.

Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.

Verkoczy L, Alt FW, Tian M.

Immunol Rev. 2017 Jan;275(1):89-107. doi: 10.1111/imr.12505. Review.

4.

Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.

Sather DN, Carbonetti S, Malherbe DC, Pissani F, Stuart AB, Hessell AJ, Gray MD, Mikell I, Kalams SA, Haigwood NL, Stamatatos L.

J Virol. 2014 Nov;88(22):12968-81. doi: 10.1128/JVI.01816-14. Epub 2014 Aug 13.

5.

HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.

Ditse Z, Muenchhoff M, Adland E, Jooste P, Goulder P, Moore PL, Morris L.

J Virol. 2018 Aug 16;92(17). pii: e00878-18. doi: 10.1128/JVI.00878-18. Print 2018 Sep 1.

6.

HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.

Wang Y, O'Dell S, Turner HL, Chiang CI, Lei L, Guenaga J, Wilson R, Martinez-Murillo P, Doria-Rose N, Ward AB, Mascola JR, Wyatt RT, Karlsson Hedestam GB, Li Y.

J Virol. 2017 Oct 13;91(21). pii: e00910-17. doi: 10.1128/JVI.00910-17. Print 2017 Nov 1.

8.
9.

Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).

Killick MA, Grant ML, Cerutti NM, Capovilla A, Papathanasopoulos MA.

Vaccine. 2015 Nov 17;33(46):6298-306. doi: 10.1016/j.vaccine.2015.09.056. Epub 2015 Oct 1.

PMID:
26432912
10.

DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Gupta S, Clark ES, Termini JM, Boucher J, Kanagavelu S, LeBranche CC, Abraham S, Montefiori DC, Khan WN, Stone GW.

J Virol. 2015 Apr;89(8):4158-69. doi: 10.1128/JVI.02904-14. Epub 2015 Jan 28.

11.

Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.

Verkoczy L, Diaz M.

Curr Opin HIV AIDS. 2014 May;9(3):224-34. doi: 10.1097/COH.0000000000000049. Review.

12.

HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.

Sliepen K, Sanders RW.

Expert Rev Vaccines. 2016;15(3):349-65. doi: 10.1586/14760584.2016.1129905. Epub 2016 Jan 8. Review.

PMID:
26654478
13.

Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?

Subbaraman H, Schanz M, Trkola A.

Retrovirology. 2018 Jul 28;15(1):52. doi: 10.1186/s12977-018-0433-2. Review.

14.

Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.

Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, Carnathan DG, Chandrashekar A, Cirelli KM, Cottrell CA, Eroshkin AM, Guenaga J, Kaushik K, Kulp DW, Liu J, McCoy LE, Oom AL, Ozorowski G, Post KW, Sharma SK, Steichen JM, de Taeye SW, Tokatlian T, Torrents de la Peña A, Butera ST, LaBranche CC, Montefiori DC, Silvestri G, Wilson IA, Irvine DJ, Sanders RW, Schief WR, Ward AB, Wyatt RT, Barouch DH, Crotty S, Burton DR.

Immunity. 2017 Jun 20;46(6):1073-1088.e6. doi: 10.1016/j.immuni.2017.05.007.

15.

Strategies for a multi-stage neutralizing antibody-based HIV vaccine.

Andrabi R, Bhiman JN, Burton DR.

Curr Opin Immunol. 2018 Aug;53:143-151. doi: 10.1016/j.coi.2018.04.025. Epub 2018 May 16. Review.

16.

Anti-HIV B Cell lines as candidate vaccine biosensors.

Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J, Lifson J, Wu X, Mascola JR, Poignard P, Binley JM, Chakrabarti BK, Schief WR, Wyatt RT, Burton DR, Nemazee D.

J Immunol. 2012 Nov 15;189(10):4816-24. doi: 10.4049/jimmunol.1202165. Epub 2012 Oct 12.

17.

Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.

Moore PL, Gorman J, Doria-Rose NA, Morris L.

Immunol Rev. 2017 Jan;275(1):217-229. doi: 10.1111/imr.12501. Review.

18.

A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.

Jones AT, Chamcha V, Kesavardhana S, Shen X, Beaumont D, Das R, Wyatt LS, LaBranche CC, Stanfield-Oakley S, Ferrari G, Montefiori DC, Moss B, Tomaras GD, Varadarajan R, Amara RR.

J Virol. 2018 Feb 12;92(5). pii: e01796-17. doi: 10.1128/JVI.01796-17. Print 2018 Mar 1.

19.

Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope.

Doores KJ, Kong L, Krumm SA, Le KM, Sok D, Laserson U, Garces F, Poignard P, Wilson IA, Burton DR.

J Virol. 2015 Jan 15;89(2):1105-18. doi: 10.1128/JVI.02905-14. Epub 2014 Nov 5. Erratum in: J Virol. 2015 Jun;89(12):6525.

20.

Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.

Girard MP, Picot V, Longuet C, Nabel GJ.

Vaccine. 2013 Jun 24;31(29):2979-83. doi: 10.1016/j.vaccine.2013.02.068. Epub 2013 Mar 13.

PMID:
23499518

Supplemental Content

Support Center